Order byBest matchMost fresh

GoodRx, Novo Nordisk and Ozempic

Digest more
GoodRx teams up with Novo Nordisk to make weight loss drugs more affordable
“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” Wendy Barnes, President and Chief Executive Officer of GoodRx, said in a news release...

Continue reading

Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk Adds Ozempic to Direct-to-Consumer Offerings, at $499 Per Month. Why GoodRx Stock Spikes.
Canada approves Ozempic to cut risk of kidney failure, heart-related deaths
Canada has approved Novo Nordisk's (NOVOb.CO) diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type-2 diabetes patie...

Continue reading

Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Novo Nordisk halves Ozempic price in US
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
“At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the...

Continue reading

US cash-paying customers can now get Ozempic for half price
US patients can now get Ozempic for half price if they can pay cash

GoodRx stock soars after striking deal to sell Novo Nordisk's GLP-1s for $499/month

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.
BioSpace2d

Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip insurance. This is not the first time Novo has partnered with a pharmacy to offer the blockbuster drugs.

Stock Movers: Novo Nordisk, GoodRX, CVS

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

GoodRx (GDRX) Stock Is Sliding Tuesday: What's Going On?

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new partnership with Novo Nordisk.

GoodRx: After A 30% Surge On The Novo News, Is The Story Just Beginning?

GoodRx Holdings, Inc.'s partnership with Novo Nordisk highlights its vital role in direct-to-consumer drug pricing. Click here to find out why GDRX is a Buy.
Feedback